Endo, Inc. has announced a definitive agreement with MC2 Therapeutics to launch Wynzora Cream in Canada through its subsidiary, Paladin Pharma Inc. The collaboration aims to bring this topical treatment for plaque psoriasis to Canadian patients, offering a novel approach to managing the chronic autoimmune condition.
Livio Di Francesco, Vice President and General Manager of Paladin, expressed enthusiasm about the partnership, stating, "We are excited to collaborate with MC2 Therapeutics to make Wynzora Cream accessible to Canadians suffering from plaque psoriasis. If approved by Health Canada, this innovative treatment will offer a unique combination of efficacy and convenience, integrating seamlessly into patients' daily routines."
Wynzora Cream: A Novel Treatment for Plaque Psoriasis
Wynzora Cream combines calcipotriene, a synthetic vitamin D3 analog, and betamethasone dipropionate, a corticosteroid, in a single cream-based formulation. This dual-action approach targets key cytokines in the immune system, including IL-23 and IL-17A/F, along with TNF-α expression, addressing the core drivers of plaque psoriasis. The cream is formulated using MC2 Therapeutics’ PAD Technology, which provides a water-based formulation designed for easy application and improved patient adherence.
Global Presence and Regulatory Status
Wynzora Cream has already gained regulatory approval and market presence in the United States and Europe. It received FDA approval in the United States on July 20, 2020, and was subsequently launched in Europe on February 18, 2022. The introduction of Wynzora Cream to Canada aims to address a significant unmet need for plaque psoriasis patients, offering them a novel treatment that balances efficacy with convenience.
Addressing Unmet Needs in Plaque Psoriasis Treatment
Plaque psoriasis is a chronic autoimmune condition affecting the skin, characterized by raised, inflamed, scaly patches. Current treatments often involve topical corticosteroids, vitamin D analogs, and systemic therapies. Wynzora Cream offers a convenient, once-daily topical option that combines the benefits of both calcipotriene and betamethasone dipropionate in a single formulation, potentially improving patient adherence and treatment outcomes.
Jesper J. Lange, CEO of MC2 Therapeutics, shared similar enthusiasm for the collaboration. "We are delighted to partner with Paladin, whose experienced team is well-equipped to bring Wynzora Cream to the Canadian market," Lange remarked. "This agreement reflects our commitment to expanding global access to Wynzora Cream, ensuring that patients with plaque psoriasis have a new, effective treatment option."
